170 related articles for article (PubMed ID: 15025411)
1. Managing hematologic toxicities: novel therapies.
Nirenberg A
Cancer Nurs; 2003 Dec; 26(6 Suppl):32S-37S. PubMed ID: 15025411
[TBL] [Abstract][Full Text] [Related]
2. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
Collantes RS; Younossi ZM
J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
[TBL] [Abstract][Full Text] [Related]
3. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
Ong JP; Younossi ZM
Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
[TBL] [Abstract][Full Text] [Related]
4. [New generation cytokines to prevent anemia and febrile neutropenia].
Fayette J; Blay JY
Bull Cancer; 2006 May; 93(5):483-7. PubMed ID: 16777626
[TBL] [Abstract][Full Text] [Related]
5. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
7. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
Biganzoli L; Untch M; Skacel T; Pico JL
Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
[TBL] [Abstract][Full Text] [Related]
8. The development of supportive-care agents for patients with cancer.
Neumann TK; Foote M
Biotechnol Annu Rev; 2003; 9():397-417. PubMed ID: 14650936
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
10. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
[TBL] [Abstract][Full Text] [Related]
11. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM
Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
Miller AA; Wang XF; Gu L; Hoffman P; Khatri J; Dunphy F; Edelman MJ; Bolger M; Vokes EE; Green MR;
J Thorac Oncol; 2008 Oct; 3(10):1159-65. PubMed ID: 18827613
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
14. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-associated hematopoietic toxicity.
Kuhn JG
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S4-7. PubMed ID: 12166034
[TBL] [Abstract][Full Text] [Related]
17. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
Dar Santos AE; Partovi N; Ford JA; Yoshida EM
Ann Pharmacother; 2007 Feb; 41(2):268-75. PubMed ID: 17299014
[TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim.
Willis F; Pettengell R
Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
[TBL] [Abstract][Full Text] [Related]
20. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Henry DH
Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
